{
    "id": 27386,
    "fullName": "DPP4 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "DPP4 positive indicates the presence of the DPP4 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1803,
        "geneSymbol": "DPP4",
        "terms": [
            "DPP4",
            "ADABP",
            "ADCP2",
            "CD26",
            "DPPIV",
            "TP103"
        ]
    },
    "variant": "positive",
    "createDate": "01/10/2018",
    "updateDate": "01/02/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12676,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, YS110 treatment resulted in a best response of stable disease in 50% (13/26) of patients with advanced solid tumors expressing DPP4, and a median progression-free survival of 43 days (PMID: 28291776).",
            "molecularProfile": {
                "id": 28832,
                "profileName": "DPP4 positive"
            },
            "therapy": {
                "id": 6573,
                "therapyName": "YS110",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10590,
                    "pubMedId": 28291776,
                    "title": "First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28291776"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28832,
            "profileName": "DPP4 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}